Publications by authors named "David Madar"

Claim this Profile
C
Correction to Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity.
Milan Bruncko, Le Wang, George S Sheppard, Darren C Phillips, Stephen K Tahir, David Madar

J Med Chem· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.
Milan Bruncko, Le Wang, George S Sheppard, Darren C Phillips, Stephen K Tahir, David Madar

J Med Chem· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-aryl-benzimidazolones as novel small molecule HSP90 inhibitors.
Milan Bruncko, Stephen K Tahir, Xiaohong Song, Jun Chen, Hong Ding, David J Madar

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the oxidative folding of lysozyme at a high protein concentration using aromatic thiols versus glutathione.
David J Madar, Amar S Patel, Watson J Lees

J Biotechnol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.
Bradley J Backes, Kenton Longenecker, Gregory L Hamilton, Kent Stewart, Chunqiu Lai, David J Madar

Bioorg Med Chem Lett· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Zhonghua Pei, Xiaofeng Li, Thomas W von Geldern, David J Madar, Kenton Longenecker

J Med Chem· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structural activity relationship of 11beta-HSD1 inhibitors with novel adamantane replacements.
Vince S C Yeh, Ravi Kurukulasuriya, David Madar, Jyoti R Patel, Steven Fung

Bioorg Med Chem Lett· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.
David J Madar, Hana Kopecka, Daisy Pireh, Hong Yong, Zhonghua Pei

J Med Chem· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors.
Zhonghua Pei, Xiaofeng Li, Kenton Longenecker, Thomas W von Geldern, Paul E Wiedeman, David J Madar

J Med Chem· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors.
Kenton L Longenecker, Kent D Stewart, David J Madar, Clarissa G Jakob, Elizabeth H Fry

Biochemistry· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis